Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14856038 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4HTR2AIDO1 | |
| SCHEMBL14857286 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4HTR2AIDO1 | |
| SCHEMBL19774140 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4HTR2AIDO1 | |
| SCHEMBL1511941 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4HTR2AIDO1 | |
| SCHEMBL14856079 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4HTR2AIDO1 | |
| SCHEMBL15001011 | 0.87 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4HTR2AIDO1 | |
| SCHEMBL14856095 | 0.87 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4HTR2AIDO1 | |
| SCHEMBL14990601 | 0.87 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4HTR2AIDO1 | |
| SCHEMBL14856094 | 0.87 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4HTR2AIDO1 | |
| SCHEMBL14990599 | 0.87 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4HTR2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2024-03-19 | — | — | US | disclosed |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CHU NANTES (FR) | 2021-01-14 | — | — | US | disclosed |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CHU NANTES (FR) | 2021-01-14 | — | — | US | disclosed |
| EP-3394058-B1 | N-[3-(3-{4-[[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY]-1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YL} -UREIDO)-PHENYL]-METHANESULFONAMIDE DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-14 | — | — | EP | disclosed |
| EP-2788345-B1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2020-06-10 | — | — | EP | disclosed |
| EP-3630759-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | Centre National De La Recherche Scientifique (FR) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215557-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-11-29 | — | — | WO | disclosed |
| US-9994565-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-12 | — | — | US | disclosed |
| US-9994565-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-12 | — | — | US | disclosed |
| WO-2015019325-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-02-12 | — | — | WO | disclosed |
| EP-2580212-B1 | Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract | CHIESI FARMA SPA (IT) | 2015-01-28 | — | — | EP | disclosed |
| US-8916708-B2 | Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-23 | — | — | US | disclosed |
| US-20130143914-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-06 | — | — | US | disclosed |
| EP-2580212-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.p.A. (IT) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154738-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-15 | — | — | WO | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-4091018-A | ANIMAL GROWTH PROMOTERS | AMERICAN CYANAMID COMPANY (US) | 1978-05-23 | — | — | US | disclosed |
| US-4049717-A | INTERMEDIATES FOR UREAS AND THIOUREAS | AMERICAN CYANAMID COMPANY (US) | 1977-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143914-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | ARG2, MAPK1, URB2 | SLC6A2 4595/4885SLC6A3 4701/4885SLC6A4 4737/4885 |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CACNA1E, KCNA1, KCNT1 | SLC6A2 2819/4885SLC6A3 2521/4885SLC6A4 2026/4885 |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CACNA1E, KCNA1, KCNT1 | SLC6A2 2819/4885SLC6A3 2521/4885SLC6A4 2026/4885 |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, P2RY4, P2RY1 | SLC6A2 1792/4885SLC6A3 2609/4885SLC6A4 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.